IDO Target Perseverence With IO Biotech's Mai-Britt Zocca, Ph.D.
Business Of Biotech · 38 minutes ·

IDO Target Perseverence With IO Biotech's Mai-Britt Zocca, Ph.D.

Under the leadership of Mai-Britt Zocca, Ph.D., IO Biotech is advancing novel, immune-modulating cancer therapies targeting IDO (indoleamine 2,3-dioxygenase). Though promising, the target fell out of favor after some high-profile misses – most notably Merck's Phase 3 failure with pembrolizumab in 2018. But Immunome's dual mechanism of action is renewing interest in the target, and Dr. Zocca is gaining confidence as the company's data grows. On this episode of the Business of Biotech, she shares the approach, how it differs from previous attempts, and how her company is working to advance its programs in the wake of IDO's fall from grace.

Comments (0)

You Must Be Logged In To Comment

Similar podcasts

Inquiries with io

A Sit With Britt

Breathe With Britt Guided Meditation

Brain Fuel with Barbara Britt

Foodist with Darya Rose, Ph.D

Whole Picture with Britt Witkin

Mai Favorite People

Listen Hunnay with Jeannie Mai